1. Home
  2. FRME vs IMNM Comparison

FRME vs IMNM Comparison

Compare FRME & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Merchants Corporation

FRME

First Merchants Corporation

N/A

Current Price

$39.01

Market Cap

2.6B

Sector

Finance

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$19.53

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRME
IMNM
Founded
1893
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.5B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
FRME
IMNM
Price
$39.01
$19.53
Analyst Decision
Buy
Strong Buy
Analyst Count
6
16
Target Price
★ $46.50
$35.20
AVG Volume (30 Days)
432.8K
★ 1.3M
Earning Date
10-21-2026
11-05-2026
Dividend Yield
★ 3.74%
N/A
EPS Growth
13.78
★ 51.40
EPS
★ 0.45
N/A
Revenue
N/A
★ $6,941,000.00
Revenue This Year
$17.08
N/A
Revenue Next Year
$5.03
$18,747.97
P/E Ratio
$87.98
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$34.66
$13.53
52 Week High
$45.33
$30.06

Technical Indicators

Market Signals
Indicator
FRME
IMNM
Relative Strength Index (RSI) 34.08 30.12
Support Level $38.84 $19.39
Resistance Level $41.77 $23.48
Average True Range (ATR) 0.66 1.12
MACD -0.05 -0.27
Stochastic Oscillator 15.59 13.81

Price Performance

Historical Comparison
FRME
IMNM

About FRME First Merchants Corporation

First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: